Drug Information

Drug General Information
Drug ID
D0S4II
Former ID
DCL000407
Drug Name
GSK1292263
Drug Type
Small molecular drug
Indication Gastric cancer; Type 2 diabetes [ICD9: 151, 250; ICD10:C16, E11] Phase 2 [523205]
Company
GSK
Structure
Download
2D MOL

3D MOL
Formula
C24H30N4O4S
Canonical SMILES
CC(C)C1=NOC(=N1)N2CCC(CC2)CCOC3=CN=C(C=C3)C4=CC=C(C=C4)<br />S(=O)(=O)C
InChI
1S/C24H30N4O4S/c1-17(2)23-26-24(32-27-23)28-13-10-18(11-14-28)12-15-31-20-6-9-22(25-16-20)19-4-7-21(8-5-19)33(3,29)30/h4-9,16-18H,10-15H2,1-3H3
InChIKey
HWRHYSUKHZYCAU-UHFFFAOYSA-N
PubChem Compound ID
71301143
Target and Pathway
Target(s) Glucose-dependent insulinotropic receptor Target Info Modulator
KEGG Pathway cAMP signaling pathway
Insulin secretion
WikiPathways Incretin Synthesis, Secretion, and Inactivation
References
Ref 523205ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.